CBR3

Across TCGA pan-cancer cohorts, CBR3 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CBR3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CBR3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CBR3 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, CCRCC, and COAD are the cancer types where CBR3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CBR3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	−1.233	<.001	12	view →
CCRCC	Female	III,IV	+0.726	<.001	11	view →
COAD	Male	III,IV	−0.576	<.001	9	view →
PDAC	Male	All	+0.628	<.001	5	view →
LSCC	Male	II,III,IV	+0.594	<.001	4	view →
OV	All	All	−0.653	.028	2	view →
LUAD	Male	All	−0.173	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CBR3–HNSC

Open the HNSC breakdown →